Hansa Biopharma AB (HNSA) Price & Analysis

Compare

10 Followers

HNSA Stock Chart & Stats

kr36.48

-kr0.04(-0.17%)

At close: Mar 06 4:00 PM EST

kr36.48

-kr0.04(-0.17%)

Day’s Range― - ―

52-Week Rangekr19.58 - kr42.98

Previous CloseN/A

Volume97.73K

Average Volume (3M)792.96K

Market Cap

kr3.09B

Enterprise Valuekr2.41B

Total Cash (Recent Filing)kr252.07M

Total Debt (Recent Filing)kr923.89M

Price to Earnings (P/E)―

Beta0.50

Next Earnings

Feb 05, 2026

EPS Estimate

-1.66

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.75

Shares Outstanding101,763,220

10 Day Avg. Volume714,369

30 Day Avg. Volume792,961

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)-4.18

Price to Sales (P/S)14.38

P/FCF Ratio-3.65

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr117.00

Price Target Upside220.72% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessPositive topline Phase 3 ConfIdeS results in the U.S. demonstrated a statistically significant and clinically meaningful improvement in eGFR at 12 months and significantly less dialysis dependency.

Market ExpansionBeyond transplantation, imlifidase and next-gen IgG cleaver HNSA-5487 are advancing in autoantibody-driven autoimmune diseases such as anti-glomerular basement membrane (anti-GBM) disease and Gullain-Barre syndrome (GBS).

Regulatory ApprovalIf approved, Idefirix would become the first FDA-approved therapy to address a substantial unmet need among highly sensitized kidney transplant patients and could represent a major commercial inflection point, with the opportunity to significantly accelerate revenue growth for Hansa.

Bears Say

Financial PerformanceHansa Biopharma reported another disappointing quarter for Idefirix, with sales coming in at just SEK30.8M, well below our SEK63M estimate, with headwinds in Germany and Spain pressuring performance.

Financial RiskRisks include financial, because the company has capital needs that exceed current cash balance.

Sales IssuesThe company reported no sales in Germany following the pause of the Eurotransplant pilot program.

Hansa Biopharma AB News

Hansa Biopharma’s Growth Potential: Buy Rating Backed by Promising Idefirix Trials and Expanding Pipeline

Thomas Smith, an analyst from Leerink Partners, has initiated a new Buy rating on Hansa Biopharma AB (HNSA)....

17d ago

Hansa Biopharma to Present at Major Healthcare Conferences

Hansa Biopharma AB ( ($SE:HNSA) ) has shared an announcement. Hansa Biopharma announced its CEO, Renée Aguiar-Lucander, will...

30d ago

Optimistic Buy Rating for Hansa Biopharma AB: Imlifidase’s Potential in Kidney Transplantation Highlighted by Key Opinion Leaders

Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Hansa Biopharma AB, retaining the price target...

30d ago

Hansa Biopharma Hosts Virtual Event on Imlifidase Phase 3 Results

Hansa Biopharma AB ( ($SE:HNSA) ) has issued an update. Hansa Biopharma AB announced a virtual event featuring...

1M ago

Hansa Biopharma Engages in Key Industry Conferences

Hansa Biopharma AB ( ($SE:HNSA) ) has issued an announcement. Hansa Biopharma announced that its CEO, Renée Aguiar-Lucander,...

1M ago

Optimistic Outlook for Hansa Biopharma AB Despite European Sales Challenges: Focus on Imlifidase Potential and US Market Entry

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Hansa Biopharma AB today and set a price...

1M ago

Hansa Biopharma’s Earnings Call: U.S. Prospects Amid European Challenges

Hansa Biopharma (($SE:HNSA)) has held its Q3 earnings call. Read on for the main highlights of the call....

1M ago

Hansa Biopharma Expands Share Capital with New Share Issue

Hansa Biopharma AB ( ($SE:HNSA) ) has issued an announcement. Hansa Biopharma has increased its registered share capital...

1M ago

Hansa Biopharma’s Imlifidase Achieves Key Milestone in U.S. Phase 3 Trial

Hansa Biopharma AB ( ($SE:HNSA) ) has issued an update. Hansa Biopharma announced that its drug imlifidase successfully...

1M ago

Hansa Biopharma Hosts Event on Imlifidase Phase 3 Results

Hansa Biopharma AB ( ($SE:HNSA) ) just unveiled an announcement. Hansa Biopharma AB announced a virtual event featuring...

1M ago

HNSA FAQ

What was Hansa Biopharma AB’s price range in the past 12 months?

Hansa Biopharma AB lowest stock price was kr19.58 and its highest was kr42.98 in the past 12 months.

What is Hansa Biopharma AB’s market cap?

Hansa Biopharma AB’s market cap is kr3.09B.

When is Hansa Biopharma AB’s upcoming earnings report date?

Hansa Biopharma AB’s upcoming earnings report date is Feb 05, 2026 which is in 54 days.

How were Hansa Biopharma AB’s earnings last quarter?

Hansa Biopharma AB released its earnings results on Oct 30, 2025. The company reported -kr1.75 earnings per share for the quarter, missing the consensus estimate of -kr1.737 by -kr0.013.

Is Hansa Biopharma AB overvalued?

According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Hansa Biopharma AB pay dividends?

Hansa Biopharma AB does not currently pay dividends.

What is Hansa Biopharma AB’s EPS estimate?

Hansa Biopharma AB’s EPS estimate is -1.66.

How many shares outstanding does Hansa Biopharma AB have?

Hansa Biopharma AB has 101,763,220 shares outstanding.

What happened to Hansa Biopharma AB’s price movement after its last earnings report?

Hansa Biopharma AB reported an EPS of -kr1.75 in its last earnings report, missing expectations of -kr1.737. Following the earnings report the stock price went down -11.027%.

Which hedge fund is a major shareholder of Hansa Biopharma AB?

Currently, no hedge funds are holding shares in SE:HNSA

Company Description

Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Hansa Biopharma AB (HNSA) Earnings & Revenues

Historic Earnings Reports

HNSA Stock 12 Month Forecast

Average Price Target

kr117.00

▲(220.72% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"kr21","49":"kr49","77":"kr77","105":"kr105","133":"kr133"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":132,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr132.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":117,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr117.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":102,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr102.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,49,77,105,133],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.2,38.95384615384615,46.707692307692305,54.46153846153846,62.215384615384615,69.96923076923076,77.72307692307692,85.47692307692307,93.23076923076923,100.98461538461538,108.73846153846154,116.49230769230769,124.24615384615385,{"y":132,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.2,37.8,44.4,51,57.599999999999994,64.2,70.8,77.39999999999999,84,90.6,97.2,103.8,110.39999999999999,{"y":117,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.2,36.646153846153844,42.09230769230769,47.53846153846153,52.98461538461538,58.43076923076923,63.87692307692308,69.32307692307693,74.76923076923077,80.21538461538462,85.66153846153847,91.1076923076923,96.55384615384615,{"y":102,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.52,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.74,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >